| NCT04717414 | Celgene | Myeloproliferative Disorders|Myelofibrosis|Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Anemia | 2021-02-25 | PHASE3 |
| NCT04143724 | Celgene|Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Beta-Thalassemia | 2019-11-07 | PHASE2 |
| NCT04539236 | Mikkael Sekeres, MD|Celgene|Bristol-Myers Squibb | Myelodysplastic Syndromes | 2021-11-09 | PHASE1|PHASE2 |
| NCT07073690 | Bristol-Myers Squibb | Myelodysplastic Syndromes | 2025-04-18 | |
| NCT07362095 | Zhujiang Hospital | Acute Leukemia | 2025-10-01 | PHASE1|PHASE2 |
| NCT05732961 | H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb | Myelodysplastic Syndromes|Myeloproliferative Neoplasm|Anemia | 2023-02-21 | PHASE2 |
| NCT06581055 | Bristol-Myers Squibb | Myelodysplastic Syndromes (MDS) | 2024-11-30 | |
| NCT06045689 | Bristol-Myers Squibb | Myelodysplastic Syndromes | 2023-10-05 | PHASE3 |
| NCT02631070 | Celgene|Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Myelodysplastic Syndromes | 2016-02-09 | PHASE3 |
| NCT07463820 | National Cancer Institute (NCI) | Myelodysplastic Syndrome | 2026-06-19 | PHASE2 |
| NCT06254781 | University Health Network, Toronto | Adult Granulosa Cell Tumor of the Ovary | 2022-05-30 | NA |
| NCT07450313 | Institute of Hematology & Blood Diseases Hospital, China | HSCT | 2026-03-14 | PHASE2 |
| NCT06113302 | M.D. Anderson Cancer Center | Myelodysplastic Syndromes | 2024-03-01 | PHASE2 |
| NCT01749514 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Anemia | 2013-01-21 | PHASE2 |
| NCT05462548 | Sun Yat-sen University | Thalassemia Major|Transfusion-dependent Anemia | 2022-07 | PHASE4 |
| NCT04477850 | Celgene | Myelodysplastic Syndromes | 2020-11-30 | PHASE2 |
| NCT01749540 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | B-Thalassemia | 2013-02-28 | PHASE2 |
| NCT05925504 | Institute of Hematology & Blood Diseases Hospital, China|Beijing Health Alliance Charitable Foundation | Lower Risk MDS Per IPSS-R | 2023-07-01 | PHASE2 |
| NCT05520749 | Fondazione Italiana Sindromi Mielodisplastiche-ETS|Istituto Clinico Humanitas | Myeloid Dysplasia | 2022-01-01 | |
| NCT07096297 | Yale University|Bristol-Myers Squibb | MDS (Myelodysplastic Syndrome) | 2025-12-16 | PHASE2 |
| NCT06517875 | GlaxoSmithKline | Primary Myelofibrosis|Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis | 2025-02-28 | PHASE2 |
| NCT01688011 | Celgene | Primary Myelofibrosis|Myelodysplastic Syndromes|Leukemia, Myeloid, Acute | 2013-12-12 | |
| NCT07075406 | Bristol-Myers Squibb | Myelodysplastic Syndromes | 2024-11-01 | |
| NCT06971185 | Bristol-Myers Squibb | Myelodysplastic Syndromes (MDS) | 2024-11-22 | |
| NCT02604433 | Celgene|Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Erythrocyte Transfusion|Beta-Thalassemia | 2016-05-02 | PHASE3 |
| NCT06164821 | Hematology department of the 920th hospital | Effect of Drug | 2024-01-01 | NA |
| NCT06006949 | Peking Union Medical College Hospital | Myelodysplastic Syndromes | 2023-08 | PHASE4 |
| NCT05924100 | Associazione Qol-one | Myelodysplastic Syndromes|Del(5Q)|Anemia|Transfusion-dependent Anemia | 2022-11-03 | PHASE2 |
| NCT03682536 | Celgene|Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Myelodysplastic Syndromes | 2019-01-02 | PHASE3 |
| NCT06596642 | Bristol-Myers Squibb | β-Thalassemia Major | 2024-08-21 | |
| NCT03194542 | Celgene | Primary Myelofibrosis|Anemia | 2017-11-15 | PHASE2 |
| NCT05664737 | Bristol-Myers Squibb | Anemia | 2022-12-09 | PHASE2 |
| NCT03342404 | Celgene|Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Thalassemia | 2018-02-05 | PHASE2 |
| NCT02268409 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | β-Thalassemia | 2014-10-20 | PHASE2 |
| NCT07539779 | Nanfang Hospital, Southern Medical University | Luspatercept|Poor Erythroid Engraftment|Hematological Malignancies|Myelofibrosis (MF) | 2026-05-01 | PHASE2|PHASE3 |
| NCT04064060 | Celgene | Myelodysplastic Syndromes (MDS)|Beta-thalassemia|Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis | 2019-08-12 | PHASE3 |
| NCT07338344 | Rongrong Liu | Transfusion-dependent β-thalassemia Patients | 2026-02-01 | PHASE2 |
| NCT06964971 | The First Affiliated Hospital of Zhejiang Chinese Medical University | Transfusion-dependent Non-severe Aplastic Anemia | 2025-05-20 | NA |
| NCT05181592 | GWT-TUD GmbH|Celgene | Myelodysplastic Syndromes | 2021-10-27 | PHASE3 |
| NCT07215975 | Bristol-Myers Squibb | β-thalassemia | 2026-02-26 | |
| NCT05891249 | Bristol-Myers Squibb | Anemia | 2023-06-05 | PHASE4 |
| NCT06788691 | Weill Medical College of Cornell University|Bristol-Myers Squibb | CCUS Clonal Cytopenia of Undetermined Significance|Anemia|Leukopenia|Thrombocytopenia|Neutropenia | 2025-03-25 | PHASE2 |
| NCT05931718 | Fondazione IRCCS Ca´ Granda, Ospedale Maggiore Policlinico | Autoimmune Hemolytic Anemia|Immune Thrombocytopenia|Chronic Idiopathic Neutropenia|Autoimmune Neutropenia|Myelodysplastic Syndromes|Cold Agglutinin Disease | 2019-06-01 | |
| NCT05949684 | Bristol-Myers Squibb | Myelodysplastic Syndromes | 2023-10-24 | PHASE3 |
| NCT02268383 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Myelodysplastic Syndromes | 2014-10-09 | PHASE2 |
| NCT06851065 | Bristol-Myers Squibb | Myelodysplastic Syndromes | 2024-08-22 | |
| NCT07465029 | Bristol-Myers Squibb | Lower-risk Myelodysplastic Syndromes (TD LR-MDS) | 2026-02-02 | |
| NCT05399732 | Bing Han|Bristol-Myers Squibb | Aplastic Anemia | 2022-12-19 | PHASE2 |
| NCT05005182 | Mayo Clinic | Myelodysplastic+Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified|Myelodysplastic+Myeloproliferative Neoplasm, Not Otherwise Specified | 2023-02-20 | PHASE2 |
| NCT05181735 | Groupe Francophone des Myelodysplasies|Celgene | MDS|Myelodysplastic Syndromes | 2022-05-18 | PHASE1|PHASE2 |
| NCT05384691 | University of Leipzig|Celgene Corporation | Myelodysplastic Syndromes|Anemia | 2022-09-27 | PHASE2 |
| NCT06424639 | Peking Union Medical College Hospital | Aplastic Anemia | 2024-05 | PHASE4 |
| NCT06927232 | Peking Union Medical College Hospital | Higher-risk Myelodysplastic Syndrome | 2025-04 | PHASE3 |
| NCT03900715 | Celgene | Myelodysplastic Syndromes | 2019-05-20 | PHASE2 |
| NCT05564390 | National Cancer Institute (NCI) | Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic+Myeloproliferative Neoplasm|Acute Myeloid Leukemia Post Cytotoxic Therapy|Acute Myeloid Leukemia, Myelodysplasia-Related|Myelodysplastic Syndrome | 2024-06-18 | PHASE2 |
| NCT05567458 | Bristol-Myers Squibb | Beta-thalassemia | 2022-10-17 | PHASE2 |
| NCT06073860 | Bristol-Myers Squibb | Myelodysplastic Syndrome|Beta Thalassemia | 2024-03-25 | |